Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
The study will be conducted as a single-center, randomized, double-blind, placebo-controlled, ascending dose study in up to 4 sequential cohorts of healthy subjects. Each cohort will enroll 8 subjects: 6 subjects will receive ITI-333 and 2 subjects will receive placebo once daily for 14 days.

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ITI-333 in Healthy Subjects

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: ITI-333
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Healthy male and female subjects between 18 and 45 years old (inclusive); BMI inclusive of 18-32 kg/m2 at screening and a minimum weight of 50 kg; Willingness to remain in the clinic for the inpatient portion of the study and return for follow-up visit(s) as required by protocol and as deemed necessary by the Investigator. Key Exclusion Criteria: Clinically significant abnormality within 2 years of Screening that in the Investigator's opinion may place the subject at risk or interfere with study outcome variables; this includes, but is not limited to, history of or current cardiac, hepatic, renal, neurologic, GI, pulmonary, endocrinologic, hematologic, or immunologic disease or history of malignancy; Clinically significant abnormal findings in vital sign assessments, including blood oxygen saturation (SpO2) < 96% and respiratory rate < 12 breaths per min; History of psychiatric condition that in the Investigator's opinion may be detrimental to participation in the study; CRP, ESR, or fibrinogen that are above normal reference ranges at Screening or Day 1.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Sequential Assignment
Interventional Model Description: Sequential ascending doses. Parallel (active, placebo) within each cohort
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort 1: 0.75 mg ITI-333 or placebo once daily for 14 days<br> | Drug: ITI-333<br>* ITI-333 oral solution<br>Other: Placebo<br>* Matching placebo<br>|
| Experimental: Cohort 2: 1.5 mg ITI-333 or placebo once daily for 14 days<br> | Drug: ITI-333<br>* ITI-333 oral solution<br>Other: Placebo<br>* Matching placebo<br>|
| Experimental: Cohort 3: 3 mg ITI-333 or placebo once daily for 14 days<br> | Drug: ITI-333<br>* ITI-333 oral solution<br>Other: Placebo<br>* Matching placebo<br>|
| Experimental: Cohort 4: 6 mg ITI-333 or placebo once daily for 14 days<br> | Drug: ITI-333<br>* ITI-333 oral solution<br>Other: Placebo<br>* Matching placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics: AUC0-tau | Area under the plasma drug concentration-time curve (AUC) from time zero to the end of dosing interval | predose and multiple timepoints up to 24 hours postdose on Days 1 and 14 | 
| Pharmacokinetics: Cmax | Maximum plasma concentration of ITI-333 and its metabolites over a dosing interval | predose and multiple timepoints up to 24 and 72 hours postdose on Days 1 and 14, respectively | 
| Pharmacokinetics: Tmax | Time of maximum plasma concentration of ITI-333 and its metabolites over a dosing interval | predose and multiple timepoints up to 24 and 72 hours postdose on Days 1 and 14, respectively | 
| Percentage of subjects with treatment-emergent adverse events |  | up to 30 days after last dose | 
| Change from baseline in systolic and diastolic blood pressure |  | Up to Day 24 | 
| Change from baseline in SpO2 |  | Up to Day 24 | 
| Change from baseline in ECG QT interval |  | Up to Day 24 | 
| Change from baseline in aspartate aminotransferase |  | Up to Day 24 | 
| Change from baseline in alanine aminotransferase |  | Up to Day 24 |